Anixa Biosciences, Inc. (ANIX) AI Stock Analysis
ANIX AI stock analysis summary
AI ResearchAnixa Biosciences, Inc. (NASDAQ: ANIX) is a clinical-stage biotechnology company focused on cancer therapies and vaccines. For the trailing twelve months ended July 31, 2026, the company generated $0 in revenue with an EPS of -$0.32. Its balance sheet holds $13.9M in cash and short-term investments against $174,000 in total debt.
- Market cap
- $92.8M
- Revenue (TTM)
- $0
- P/E
- —
- 1Y return
- -39.3% S&P 500 16.8%
- Avg. target
- $9.75 265.2% vs last close
Bull case
- Analysts maintain a bullish consensus with 3 Strong Buy ratings and 1 Buy rating, with an average target price of $9.75 offering a 265.2% premium over the $2.67 close.
- The balance sheet is minimally leveraged with $13.9M in cash against just $174,000 in total debt, resulting in a current ratio of 8.54.
- The company demonstrated earnings consistency relative to consensus, beating EPS expectations in 3 of the last 4 quarters.
Bear case
- Trailing twelve-month revenue was $0 as of July 31, 2026, and consensus estimates expect $0 in revenue for the fiscal years ending in 2026 and 2027.
- Cash flow generation remains negative, with free cash flow standing at -$6.2M in FY2023 and ongoing dilution reflected by a 13.5% share count increase over 5 years.
- The stock has lagged the broader market considerably, declining 39.3% over the past year compared to a 16.8% return for the S&P 500.
What Anixa Biosciences does
Anixa Biosciences, Inc. is a biotechnology company developing therapies and vaccines for oncology and infectious diseases. Its therapeutic portfolio features a chimeric endocrine receptor T-cell therapy, utilizing CAR-T technology to treat ovarian cancer, as well as anti-viral drug candidates targeted against COVID-19. On the vaccine side, the company is advancing a preventative vaccine for ovarian cancer and an immunotherapy vaccine targeting triple-negative breast cancer. Originally founded in 1982 as ITUS Corporation, the company rebranded to Anixa Biosciences in October 2018 and operates out of San Jose, California.
Growth and profitability
Over the 5-year period from FY2017 to FY2023, revenue experienced a CAGR of -10.3%. Annual revenue has been volatile, reporting $1.1M in FY2018, $250,000 in FY2019, $512,000 in FY2021, $2.47B in FY2022, and $210,000 in FY2023. In FY2023, operating margin stood at -5243.3% and net income was -$9.8M, representing an EPS of -$0.32 alongside $4.8M in R&D expenses. For the trailing twelve months ended July 31, 2026, revenue was $0, operating margin was 0.0%, and EPS was -$0.32.
Balance sheet and cash flow
As of July 31, 2026, Anixa Biosciences held $13.9M in cash and short-term investments and $174,000 in total debt, yielding net cash of $13.7M. Shareholders' equity was $14.5M out of $15.1M in total assets. The company maintains a current ratio of 8.54 and a debt-to-equity ratio of 0.01. Free cash flow was -$6.2M in FY2023, following -$6.5M in FY2022. Over a 5-year period through FY2025, the company's share count increased by 13.5%.
Valuation and performance
With a market cap of $92.8M and an enterprise value of $82.3M, ANIX trades at a price-to-sales multiple of 377.8x and an EV-to-revenue multiple of 274.8x, compared to the median of its US-listed Healthcare peers of 4.1x for price-to-sales. Its price-to-book multiple is 6.7x. Over the past year, the stock returned -39.3%, while the S&P 500 (SPY) returned 16.8%. Over a 5-year timeframe, the stock declined 39.2% against an 83.0% gain for the benchmark.
What analysts expect
Wall Street coverage consists of 3 Strong Buy ratings and 1 Buy rating. The mean price target is $9.75, which sits 265.2% above the last closing price of $2.67 on October 16, 2026. For the current fiscal year ending October 31, 2026, consensus estimates project $0 in revenue and an EPS of -$0.31, representing 8.8% earnings growth. Over the last 4 quarters, the company beat EPS estimates 3 times.
Key risks and what to watch
- The company generated $0 in revenue over the trailing twelve months, maintaining reliance on cash reserves to fund R&D and operations.
- Negative profitability is reflected in a return on equity of -73.2% and a return on assets of -41.9% for the trailing twelve months.
- Shareholder dilution has occurred over time, with the total share count expanding 13.5% over the 5-year period through FY2025.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this ANIX AI stock analysis
This page is an AI-written research summary of Anixa Biosciences, Inc. (ANIX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: ANIX income statement, ANIX balance sheet, ANIX key metrics, ANIX analyst forecast, ANIX chart. See the ANIX stock overview for the latest quote and news.
ANIX AI stock analysis FAQ
What is Anixa Biosciences' current cash position?
As of July 31, 2026, Anixa Biosciences reported $13.9M in cash and short-term investments, with total debt of $174,000 and net cash of $13.7M.
Does Anixa Biosciences pay a dividend?
No, Anixa Biosciences does not pay a dividend.
What are Wall Street analysts forecasting for ANIX stock?
Analysts have 3 Strong Buy ratings and 1 Buy rating on ANIX, with an average price target of $9.75, which is 265.2% above its closing price of $2.67 on October 16, 2026.
What were Anixa Biosciences' recent earnings and revenue?
For the trailing twelve months ended July 31, 2026, Anixa Biosciences recorded $0 in revenue and an EPS of -$0.32, compared to an EPS of -$0.32 and $210,000 in revenue in FY2023.